Sarepta's Duchenne gene therapy clears study hurdle, although questions linger
Bio Pharma Dive
MAY 18, 2021
A version of the treatment made at commercial scale looks similar to what Sarepta used in early testing. But the findings are no longer the last step before an approval filing, as the company once hoped.
Let's personalize your content